Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMC 310911

Next Previous
X
Search
Drug Profile

TMC 310911

Alternative Names: ASC-09; TMC-310911

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland
  • Class Antiretrovirals
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy) in Ireland (PO, Liquid)
  • 13 Apr 2020 Phase-II development is ongoing for HIV-1 infections (Monotherapy, Treatment-naïve) in Germany and phase I development is ongoing for HIV-1 infections (Combination therapy) in Ireland
  • 01 Oct 2016 Tibotec Pharmaceuticals withdraws a phase I trial (PEPI-TiDP23-C104) in healthy volunteers prior to enrollment due to a strategic decision (NCT00908414)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top